The Alzheimer’s disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Seminal studies using post-mortem brains of patients with Alzheimer's disease evidenced aberrant insulin-like growth factor 1 receptor (IGF1R) signalling. Addressing causality, work in animal models recently demonstrated that long-term suppression of IGF1R signalling alleviates Alzheimer's disease progression and promotes neuroprotection. However, the underlying mechanisms remain largely elusive. Here, we showed that genetically ablating IGF1R in neurons of the ageing brain efficiently protects from neuroinflammation, anxiety and memory impairments induced by intracerebroventricular injection of amyloid-β oligomers. In our mutant mice, the suppression of IGF1R signalling also invariably led to small neuronal soma size, indicative of profound changes in cellular homeodynamics. To gain insight into transcriptional signatures leading to Alzheimer's disease-relevant neuronal defence, we performed genome-wide microarray analysis on laser-dissected hippocampal CA1 after neuronal IGF1R knockout, in the presence or absence of APP/PS1 transgenes. Functional analysis comparing neurons in early-stage Alzheimer's disease with IGF1R knockout neurons revealed strongly convergent transcriptomic signatures, notably involving neurite growth, cytoskeleton organization, cellular stress response and neurotransmission. Moreover, in Alzheimer's disease neurons, a high proportion of genes responding to Alzheimer's disease showed a reversed differential expression when IGF1R was deleted. One of the genes consistently highlighted in genome-wide comparison was the neurofilament medium polypeptide Nefm. We found that NEFM accumulated in hippocampus in the presence of amyloid pathology, and decreased to control levels under IGF1R deletion, suggesting that reorganized cytoskeleton likely plays a role in neuroprotection. These findings demonstrated that significant resistance of the brain to amyloid-β can be achieved lifelong by suppressing neuronal IGF1R and identified IGF-dependent molecular pathways that coordinate an intrinsic program for neuroprotection against proteotoxicity. Our data also indicate that neuronal defences against Alzheimer's disease rely on an endogenous gene expression profile similar to the neuroprotective response activated by genetic disruption of IGF1R signalling. This study highlights neuronal IGF1R signalling as a relevant target for developing Alzheimer's disease prevention strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice
Holzenberger, M., Dupont, J., Ducos, B., Leneuve, P., Géloën, A., Even, P. C., Cervera, P., & Le Bouc, Y. (2003) · Nature · doi:10.1038/nature01298 · Cited by 2,109 · cited 1×
“Investigating the complex mechanisms of ageing provided strong evidence that blocking insulin-like growth factor (IGF) pathways prolongs lifespan in various species, includ- ing mammals (Holzenberger et al., 2003; Kappeler et al., 2008; Kenyon, 2010; Xu et al., 2014; Milman et al., 2016).”
BackgroundSelf-citationTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 5×
“…in in- sulin like growth factor 1 receptor (IGF1R) expression and downstream signalling molecules, coupled with insulin and IGF1 resistance have also been demonstrated, although causality remains unclear (Steen et al., 2005; Moloney et al., 2010; Bomfim et al., 2012; Talbot et al., 2012).”
BackgroundInfluentialSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“…in in- sulin like growth factor 1 receptor (IGF1R) expression and downstream signalling molecules, coupled with insulin and IGF1 resistance have also been demonstrated, although causality remains unclear (Steen et al., 2005; Moloney et al., 2010; Bomfim et al., 2012; Talbot et al., 2012).”
BackgroundJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 1×
“APP/PS1 mice is under way but plaques are still rare and neuroinflammation limited (Jankowsky et al., 2004), allowing us to record the early adaptive response to amyloid-b accumulation in CA1 neurons.”
BackgroundMoloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · cited 1×
“…in in- sulin like growth factor 1 receptor (IGF1R) expression and downstream signalling molecules, coupled with insulin and IGF1 resistance have also been demonstrated, although causality remains unclear (Steen et al., 2005; Moloney et al., 2010; Bomfim et al., 2012; Talbot et al., 2012).”
BackgroundInterventions to slow aging in humans: are we ready?
Longo, V. D., Antebi, A., Bartke, A., Barzilai, N., Brown‐Borg, H. M., Caruso, C., Curiel, T. J., Cabo, R., Franceschi, C., Gems, D., et al. (2015) · Aging Cell · doi:10.1111/acel.12338 · Cited by 592 · cited 1×
“Recently, inhibition of IGF1 and its principal regulator growth hormone has been proposed as a promising strategy to retard human ageing and extend healthy lifespan (Longo et al., 2015).”
Background: Cellular scaling rules for rodent brains.
Herculano-Houzel, S., Mota, B., & Lent, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604911103 · Cited by 579 · cited 1×
“In accordance with the relative proportion of neurons versus other cell types (Herculano-Houzel et al., 2006), results indicated that IGF1R was ablated in almost all CaMKII -positive hippocampal neurons.”
ResultScanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model
Leinenga, G., & Götz, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2512 · Cited by 498 · cited 2×
“Total length per microglia was determined in motor cortex using AnalyzeSkeleton (ImageJ) (Leinenga and Götz, 2015).”
MethodRegulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · cited 2×
“…reduction in soma size, specifically of apical cytoplasm and primary dendrite in response to IGF1R deletion (Gontier et al., 2015), or after interfering with downstream PI3k-Akt-mTOR signalling in mice (Tavazoie et al., 2005; Cloetta et al., 2013; Thomanetz et al., 2013; Goebbels et al., 2017).”
BackgroundFerreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373 · cited 1×
“Neuronal IGF1R knockout in old mice alleviates cognitive deficits induced by amyloid-b oligomers AbOs are considered key mediators of synaptic and cognitive impairments in Alzheimer’s disease (Lesné et al., 2013; Ferreira et al., 2015).”
Background
Cited by
Wingo, A. P., Dammer, E. B., Breen, M. S., Logsdon, B. A., Duong, D. M., Troncosco, J. C., Thambisetty, M., Beach, T. G., Serrano, G. E., Reiman, E. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09613-z · Cited by 211
Ferreira, S. T. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12959 · Cited by 59
Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations
Cadiz, M. P., Gibson, K. A., Todd, K. T., Nascari, D. G., Massa, N., Lilley, M. T., Olney, K. C., Al-Amin, M. M., Jiang, H., Holtzman, D. M., et al. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20231363 · Cited by 55
“Notably, neurofilament genes Nefm , Nefl , and Nefh are increased in both amyloid mouse models (George et al., 2017) and AD patients (He et al., 2020), with NEFL in plasma and cerebrospinal fluid used as a biomarker for AD.”
BackgroundAmelioration of amyloid β‐FcγRIIb neurotoxicity and tau pathologies by targeting LYN
Gwon, Y., Kim, S.-H., Kim, H. T., Kam, T.-I., Park, J., Lim, B., Cha, H., Chang, H.-J., Hong, Y. R., & Jung, Y.-K. (2019) · The FASEB Journal · doi:10.1096/fj.201800926r · Cited by 20
Danziger, R., Fuchs, D.-T., Koronyo, Y., Rentsendorj, A., Sheyn, J., Hayden, E. Y., Teplow, D. B., Black, K. L., Fuchs, S., Bernstein, K. E., et al. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1179315 · Cited by 16
Metadata
- Authors
- George, C., Gontier, G., Lacube, P., François, J.-C., Holzenberger, M., & Aïd, S.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-06-08
- Volume
- 140
- Issue
- 7
- Pages
- 2012-2027
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2622919480
- Cited by
- 84
- References
- 17
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Alzheimer’s disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons. https://app.cochat.ai/papers/10.1093/brain/awx132
- The paper
- George, C., Gontier, G., Lacube, P., François, J.-C., Holzenberger, M., & Aïd, S. (2017). The Alzheimer’s disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons. Brain. https://doi.org/10.1093/brain/awx132
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.